Azenta (AZTA) Stock News, May-Nov 2025

Azenta (Nasdaq: AZTA) announced a strategic partnership with the PRECEDE Foundation on Nov 4, 2025 to support early detection of pancreatic cancer by providing secure biorepository storage and streamlined logistics for PRECEDE study samples.

PRECEDE unites more than 60 academic medical centers and maintains the world's largest high-risk patient cohort combining longitudinal clinical data with biospecimen tracking. Pancreatic cancer currently has a five-year survival rate of 13%, and PRECEDE's stated goal is to raise that to 50% within the next decade. Azenta frames the agreement as reinforcing its position in sample management for clinical and diagnostic research and will support PRECEDE ahead of its Annual Meeting in November.

Azenta (Nasdaq: AZTA) will host an Investor Day on Wednesday, December 10, 2025 at its biorepository facility in Indianapolis, Indiana. The event runs 8:30 AM–3:30 PM ET and includes an invite-only morning facility tour plus afternoon executive presentations and Q&A led by John Marotta (CEO) and Lawrence Lin (EVP & CFO).

The afternoon presentations will be webcast beginning at 1:00 PM ET, with a replay available the following day on Azenta's Investor Relations website. In-person attendance is by invitation and requires advanced registration.

Azenta (Nasdaq: AZTA) reported Q3 fiscal 2025 financial results with revenue from continuing operations at $144 million, flat year-over-year with a 2% organic decline. The company's performance showed mixed results across segments, with Multiomics revenue up 4% to $66 million, while Sample Management Solutions declined 4% to $78 million.

Notable improvements include Adjusted EBITDA of $18 million with a margin of 12.3%, up 260 basis points year-over-year, and Non-GAAP Diluted EPS of $0.19, up from $0.14 last year. The company maintains a strong financial position with $565 million in cash and equivalents. Azenta reiterated its fiscal 2025 guidance, expecting 3-5% organic revenue growth and approximately 300 basis points of Adjusted EBITDA margin expansion.

Azenta (Nasdaq: AZTA) has announced a strategic collaboration with Frenova and Nephronomics to advance genomic research in nephrology through the MyReason® genomics research program. The initiative has already registered over 35,000 participants and aims to reach 50,000 participants within two years.

Azenta will provide genomic sequencing through GENEWIZ and manage sample storage in its global biorepository network. Nephronomics, which holds exclusive commercial rights to the MyReason dataset, will utilize AI/machine learning models to analyze the comprehensive cardio-kidney-metabolic (CKM) disease data to identify novel disease subtypes, protective genetic variants, and therapeutic targets.

Fresenius Medical Care (NYSE:FMS) announced a strategic collaboration between its research organization Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences to advance genomic analysis of kidney disease through the My Reason® genomics program.

The collaboration leverages Frenova's registry of over 35,000 participants (targeting 50,000 in two years) to create the world's largest cardio-kidney-metabolic disease database. GENEWIZ will provide DNA sequencing and biospecimen storage, while Nephronomics holds exclusive commercial rights to develop targeted therapies using AI/ML models.

This initiative aims to transform kidney care through personalized medicine by analyzing genetic mechanisms underlying kidney, cardiovascular, and metabolic diseases.

Azenta (Nasdaq: AZTA) announced its participation in the upcoming 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The company's management team will attend the virtual event scheduled for Tuesday, August 12, 2025. This conference provides an opportunity for investors and analysts to engage with Azenta's leadership through one-on-one meetings.

Azenta (Nasdaq: AZTA) has scheduled its fiscal third quarter 2025 earnings announcement for Tuesday, August 5, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results for the quarter ended June 30, 2025.

Stakeholders can access the live webcast through the company's investor relations website. A replay of the event will become available starting at 8:30 a.m. ET on August 6, 2025.

Azenta's GENEWIZ division has formed a strategic partnership with Form Bio to enhance adeno-associated virus (AAV) gene therapy development. The collaboration integrates GENEWIZ's next-generation sequencing services with Form Bio's AI-powered analysis pipelines to improve AAV gene therapy development workflows.

The partnership combines GENEWIZ's capabilities in synthesis, packaging of transgene expression cassettes, and long-read sequencing services with Form Bio's comprehensive AAV Genome Integrity Characterization using LAAVA software. This integration aims to streamline processes, reduce development time and costs, and provide better insights into AAV capsid contents for improved safety, efficacy, and manufacturability.

The partnership will be officially launched at the 27th Annual ASGCT Meeting in May 2025, where both companies will present their collaborative research.

Azenta (NASDAQ: AZTA) reported its Q2 FY2025 financial results with revenue of $143 million, showing a 5% year-over-year increase and 6% organic growth. The company's Sample Management Solutions revenue grew 8% to $80 million, while Multiomics revenue increased 2% to $64 million. Despite revenue growth, Azenta reported a GAAP operating loss of $16 million with operating margin at -11.3%. The company maintained strong liquidity with $540 million in cash and equivalents. Adjusted EBITDA was $14 million with a 10% margin, showing a 400 basis point improvement year-over-year. Management reiterated its FY2025 guidance, expecting organic revenue growth of 3-5% and adjusted EBITDA margin expansion of approximately 300 basis points.